(Q38842531)

6 September 2017

1 reference

title

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk (English)

1 reference

6 September 2017

Michel Farnier

1

1 reference

6 September 2017

1 July 2016

1 reference

Current cardiology reports

6 September 2017

1 reference

6 September 2017

18

1 reference

6 September 2017

7

1 reference

6 September 2017

65

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-016-0743-8

6 September 2017

0 references

cites work

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9: a key modulator of cardiovascular health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

An evaluation of alirocumab for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The role of microsomal triglyceride transfer protein inhibitors in the treatment of patients with familial hypercholesterolemia: risks, benefits, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled,

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Triglycerides and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Remnant cholesterol as a causal risk factor for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Mendelian randomization of blood lipids for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Loss-of-function mutations in APOC3, triglycerides, and coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Novel therapeutics in hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Recent advances in pharmacotherapy for hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Targeting APOC3 in the familial chylomicronemia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The potential of cholesteryl ester transfer protein as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Lipoprotein(a), cardiovascular disease, and contemporary management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Lipoprotein(a) as a cardiovascular risk factor: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Current therapies for lowering lipoprotein (a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-016-0743-8

Targeting PCSK9 for the treatment of hypercholesterolemia.

21 January 2018

1 reference

12 December 2020

HDL-targeted therapies: progress, failures and future

1 reference

12 December 2020

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

1 reference

12 December 2020

Evolocumab (AMG 145) for primary hypercholesterolemia

1 reference

12 December 2020

IMPROVE-IT and genetics reaffirm the causal role of LDL in Cardiovascular Disease

1 reference

12 December 2020

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

1 reference

12 December 2020

CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects

1 reference

12 December 2020

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

1 reference

12 December 2020

10.1007/S11886-016-0743-8

Identifiers

DOI

1 reference

PubMed ID

27216845

Dimensions Publication ID

6 September 2017

1042920232

0 references

Fatcat ID

release_22rlp5xnp5gzdmq47xz2soeivm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/22rlp5xnp5gzdmq47xz2soeivm

24 November 2022

mapped directly with Wikidata item

PubMed ID

27216845

1 reference

PubMed ID

27216845